Shares of biotech giant Celgene (CELG) may be worth $200 per share if peak sales of late-stage assets, including luspatercept, ozanimod, and GED301 are met, said analyst Ying Huang. LUSPATERCEPT: Luspatercept is an experimental drug in clinical trials for the
July 10, 2017